Ensign Peak Advisors
IRWD icon

Ensign Peak Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Ensign Peak Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-85,392
Closed -$378K – 1705
2024
Q4 		$378K Hold
85,392
– – ﹤0.01% 1655
2024
Q3 		$352K Hold
85,392
– – ﹤0.01% 1665
2024
Q2 		$557K Hold
85,392
– – ﹤0.01% 1576
2024
Q1 		$744K Sell
85,392
-4,308
-5% -$52.3K ﹤0.01% 1499
2023
Q4 		$1.03M Hold
89,700
– – ﹤0.01% 1357
2023
Q3 		$864K Buy
89,700
+500
+0.6% +$4.9K ﹤0.01% 1312
2023
Q2 		$949K Hold
89,200
– – ﹤0.01% 1307
2023
Q1 		$938K Hold
89,200
– – ﹤0.01% 1291
2022
Q4 		$1.11M Buy
89,200
+63,950
+253% +$725K ﹤0.01% 1083
2022
Q3 		$262K Buy
+25,250
New +$286K ﹤0.01% 1767

Other funds holding IRWD

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ensign Peak Advisors's IRWD Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2025, closing a stake of 85,392 shares — an estimated $378K sold.

Ensign Peak Advisors first reported a position in IRWD in Q3 2022 and held it in 10 quarters. The position peaked at $1.11M in Q4 2022. 200 funds tracked by Wall St. Rank hold IRWD as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Ironwood Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 85,392 Ironwood Pharmaceuticals shares in Q1 2025, an estimated $378K.
  • Ensign Peak Advisors first reported a position in Ironwood Pharmaceuticals in Q3 2022 and held it in 10 quarters.
  • Ensign Peak Advisors's Ironwood Pharmaceuticals position peaked at $1.11M in Q4 2022.
  • 200 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.